Mirador Capital Partners LP Has $2.44 Million Stake in 10x Genomics $TXG

Mirador Capital Partners LP reduced its holdings in shares of 10x Genomics (NASDAQ:TXG) by 17.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 63,636 shares of the company’s stock after selling 13,657 shares during the quarter. Mirador Capital Partners LP’s holdings in 10x Genomics were worth $2,440,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TXG. ARK Investment Management LLC raised its position in shares of 10x Genomics by 6.6% in the fourth quarter. ARK Investment Management LLC now owns 12,667,369 shares of the company’s stock valued at $206,605,000 after purchasing an additional 779,973 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its stake in 10x Genomics by 2.1% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 5,492,189 shares of the company’s stock valued at $89,578,000 after buying an additional 110,970 shares during the last quarter. Amova Asset Management Americas Inc. grew its stake in 10x Genomics by 2.0% in the 4th quarter. Amova Asset Management Americas Inc. now owns 5,486,153 shares of the company’s stock valued at $89,424,000 after buying an additional 109,270 shares during the last quarter. Millennium Management LLC raised its holdings in 10x Genomics by 84.7% in the 3rd quarter. Millennium Management LLC now owns 5,437,969 shares of the company’s stock valued at $63,570,000 after acquiring an additional 2,494,142 shares during the period. Finally, Quantinno Capital Management LP lifted its position in 10x Genomics by 16.0% during the first quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock worth $114,892,000 after acquiring an additional 744,558 shares during the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on TXG shares. Bank of America boosted their price objective on 10x Genomics from $21.00 to $30.00 and gave the stock a “neutral” rating in a report on Monday, April 20th. Zacks Research lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Leerink Partners lifted their price target on 10x Genomics from $23.00 to $40.00 and gave the stock a “market perform” rating in a report on Friday, July 17th. Canaccord Genuity Group boosted their price target on 10x Genomics from $32.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Finally, Barclays upped their price objective on 10x Genomics from $30.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $32.08.

Insider Buying and Selling

In related news, Director Shehnaaz Suliman sold 5,723 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $32.63, for a total transaction of $186,741.49. Following the sale, the director owned 31,722 shares of the company’s stock, valued at $1,035,088.86. This represents a 15.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 11,595 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $24.44, for a total value of $283,381.80. Following the transaction, the insider owned 502,000 shares in the company, valued at approximately $12,268,880. This trade represents a 2.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 91,309 shares of company stock valued at $2,581,357. 8.84% of the stock is currently owned by corporate insiders.

10x Genomics Stock Down 0.8%

NASDAQ TXG opened at $47.46 on Thursday. The firm has a 50-day moving average price of $38.46 and a two-hundred day moving average price of $27.27. 10x Genomics has a 12-month low of $11.16 and a 12-month high of $50.34. The company has a market capitalization of $6.03 billion, a P/E ratio of -279.18 and a beta of 2.03.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Thursday, May 7th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.19. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. The company had revenue of $150.84 million for the quarter, compared to analysts’ expectations of $146.41 million. During the same period last year, the firm earned ($0.28) earnings per share. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Equities analysts expect that 10x Genomics will post -0.78 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.